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Recently, there is increasing interest in the role of peripheral mineralocorticoid receptors (MR) to
modulate pain, but their localization in neurons and glia of the periphery and their distinct involvement
in pain control remains elusive. In naive Wistar rats our double immunoﬂuorescence confocal micro-
scopy of the spinal cord, dorsal root ganglia, sciatic nerve and innervated skin revealed that MR pre-
dominantly colocalized with calcitonin-gene-related peptide (CGRP)- and trkA-immunoreactive (IR)
nociceptive neurons and only marginally with myelinated trkB-IR mechanoreceptive and trkC-IR pro-
prioreceptive neurons underscoring a pivotal role for MR in the modulation of pain. MR could not be
detected in Schwann cells, satellite cells, and astrocytes and only scarcely in spinal microglia cells
excluding a relevant functional role of glia-derived MR at least in naïve rats. Intrathecal (i.t.) and
intraplantar (i.pl.) application of increasing doses of the MR selective agonist aldosterone acutely
increased nociceptive behavior which was reversible by a MR selective antagonist and most likely due to
non-genomic effects. This was further substantiated by the ﬁrst identiﬁcation of membrane bound MR
speciﬁc binding sites in sensory neurons of dorsal root ganglia and spinal cord. Therefore, a crucial role of
MR on nociceptive neurons but not on glia cells and their impact on nociceptive behavior most likely due
to immediate non-genomic effects has to be considered under normal but more so under pathological
conditions in future studies.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mineralocorticoid receptors and their endogenous ligand aldo-
sterone are best known for their control of thewater and electrolyte
balance in the kidney and their involvement in volume and blood
pressure regulation (Te Riet et al., 2015). In addition, aldosterone
has also been reported to promote inﬂammation, ﬁbrosis, and
remodeling in the heart and vasculature (Ferrario and Schiffrin,
2015; Young and Rickard, 2012). Interestingly in older studies, a
combination of aldosterone and its antagonist spironolactone
revealed an immunosuppressive effect in allogenic skin graftssiology and Intensive Care
linikum and Campus Charite
.
ousa).
r Ltd. This is an open access article(Baethmann et al., 1971), multiple sclerosis (Mertin et al., 1972), and
progressive systemic sclerosis (Altmeyer et al., 1985). All these ef-
fects occur by the classical pathway at which aldosterone easily
diffuses the cellular membrane, binds to its cytoplasmic MR and e
upon dissociation of chaperons and formation of MR dimers - is
translocated to the nucleus resulting in the enhanced or inhibited
expression of several genes (Te Riet et al., 2015). The effects of
aldosterone via intracellular MR are usually characterized by a 45-
min up to several hours lag period (Funder, 2005). In contrast to
these genomic effects more rapid non-genomic effects have also
been demonstrated particularly in neurons of the nervous system
(Groeneweg et al., 2012). Corticosteroids for example rapidly alter
neuronal excitability throughout the brain and as a consequence
regulate adaptive behavior and memory (Groeneweg et al., 2012).
Recently, increasing interest has focused on the role of MR in
different conditions of pain. In a model of chronic compression ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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jection of the MR antagonist spironolactone over three days
resulted in a signiﬁcant reduction of mechanical allodynia (Gu et al.,
2011; Sun et al., 2012). In another model of zymosan-induced local
inﬂammation of the L5 dorsal root ganglion, the combined local
application of zymosan with the MR antagonist eplerenone
reduced for an extended period of time the mechanical hypersen-
sitivity (Dong et al., 2012). In the same study MR were shown in
dorsal root ganglia to colocalize with the pan-neuronal cell marker
NeuN and eplerenone treatment apparently decreased the number
of activated satellite glia cells. Since these effects occurred with
some delay and lasted several days, they were most likely due to
genomic effects of the MR. Up to now, evidence for the exact sub-
populations of DRG neurons and glia cells that express MR and for
putative short lasting non-genomic effects resulting from neuronal
membrane bound MR is lacking.
Therefore, we systematically investigated in naive rats i) the
presence of MR speciﬁc mRNA and receptor protein in spinal cord,
dorsal root ganglia and innervating sciatic nerve compared to
kidney; ii) the localization of MR in neurons, astrocytes and
microglia of the spinal cord, iii) the localization of MR to myelin-
ated, unmyelinated, nociceptive, mechanoreceptive and proprio-
ceptive neurons in dorsal root ganglia; iv) the characterization of
MR-ir nerve terminals in the subepidermal and epidermal layer
of the skin; v) the changes in nociceptive behavior following the
local i.pl. or i.th. administration of a MR selective agonist with and
without antagonist; vi) the evidence for membrane bound MR by
saturation binding with the radiolabeled MR selective ligand [3H]
aldosterone.2. Methods
2.1. Reagents
The following drugs were used: aldosterone, canreonate-K
(Sigma-Aldrich, St. Louis, MO, USA); doses were calculated -
where applicable - in terms of the free base. Canreonate-K was
dissolved in NaCl 0.9%, aldosterone was dissolved in a vehicle
composed of 10% ethanol and 90% normal saline, as described
previously (Gravez et al., 2013). Routes and volumes of drug
administrationwere i.t. 20 mL and i.pl. 100 mL. Intrathecal injections
were performed under inhalational anesthesia with the rat in the
elevated lumbar position. Intraplantar injections were given underTable 1
Characterization of primary antibodies used.
Antigen Immunogen
MR a 142-amino-acid peptide sequence from the unique DNA-bindin
domain of the rat MR gene
MR amino acids 1e300 of the human MR that is recommended for t
detection of mouse, rat and human MR
Calcitonin-Gene
Related Peptide
synthetic entire calcitonin gene-related peptide
trkA extracellular domain Ala33-Pro418 of rat trkA
NF200 carboxy terminal tail segment of dephosphorylated NF200
trkB extracellular domain Cys32-Thr429 of recombinant mouse trkB
trkC extracellular domain Cys32-Thr429 of recombinant mouse trkC
GFAP clone G-A-5
CD11b clone OX-42inhalational anesthesia into the subcutaneous tissue of the
glabrous skin directly proximal to the callosities of the toes. The
drug or its solvent were injected into the intrathecal L3-L4 inter-
space (spontaneous tail movement being a positive indication for
correct i.t. positioning) with a 30-gauge needle connected to a 50 mL
syringe. In accordance with previous studies (Myers and Van
Meerveld, 2009; Khan and Bakshi, 2009), separate groups of ani-
mals for each dose and injection technique received i.pl. or i.t. ad-
ministrations of different doses of: aldosterone (i.pl. 25e100 mg or
i.t. 4e40 mg) with and without canreonate-K (150e500 mg). Control
animals received vehicle treatment. Experiments were performed
in a blinded way to the drugs and doses applied.
2.2. Animals
Experiments were conducted in male Wistar rats (200e250 g)
(breeding facility, Charite-Universit€atsmedizin Berlin, Germany)
after approval by the local animal care committee and in accor-
dance with the European Directive on the protection of animals
used for scientiﬁc purposes (2010/63/EU).
2.3. Characterization of antibodies
The species, sources, dilutions, and immunogens of the primary
antibodies used in this study are summarized in Table 1.
2.4. Tissue preparation
Rats were deeply anesthetized with isoﬂurane and the subcu-
taneous paw tissue, sciatic nerve, dorsal root ganglia, spinal cord,
and kidney were removed from adult rats for subsequent qRT-PCR
and western blot experiments.
2.5. RT-PCR
The total RNAwas prepared from kidney, DRG and spinal cord of
rats with the commercially available Kit Qiazol Lysis Reagent,
(Qiagen, Hilden, Germany) according to the manufacturer's proto-
col. 500 ng total RNA, measured by Nanodrop (Peqlab) was applied
for transcription of cDNA using Omniscript RT Kit (Qiagen, Hilden,
Germany) as followed: 0.5 mM dNTP,1 mMRandom Primer,10 units
RNase Inhibitor and 4 units Omnisript reverse Transcriptase.
Samples were incubated at 42 C for 1 h and cDNA were storedManufacturer, species, type, catalogue number Dilution
used
g a gift from M. Kawata (Kyoto Prefectural University of Medicine,
Japan), rabbit polyclonal, # Ito et al., 2000
1:2000
he Santa Cruz Biotechnology (USA), rabbit polyclonal, # sc-11412,
Kapoor et al., 2008
1:1000
Peninsula Laboratories (CA, USA), guinea pig polyclonal, # T-5027,
Mousa et al., 2013
1:1000
R&D Systems (USA), goat polyclonal, # AF1056, Matsumoto et al.,
2012
1:1000
Sigma-Aldrich (USA), mouse monoclonal # N0142/N52, Kestell et al.,
2015
1:1000
R&D Systems (USA), goat polyclonal, # AF1494, Matsumoto et al.,
2012
1:1000
R&D Systems (USA), goat polyclonal, # AF1404, Matsumoto et al.,
2012
1:1000
Sigma-Aldrich (USA), mouse monoclonal # G3893, Liu and Chien,
2012
1:1000
AbD Serotec (Germany), mouse monoclonal # MCA275R, Robinson
et al., 1986
1:1000
M. Shaqura et al. / Neuropharmacology 107 (2016) 251e261 253at 20 C. The following speciﬁc primers for MR were used:
(Ensemble Accession No: NM_013131.1), Forward primer; : 50-
CCAAGGTACTTCCAGGATTTAAAAAC-30, Reverse primer; 50-AAC-
GATGATAGACACATCCAAGAATACT-30 Taqman® qRT-PCR was per-
formed with a SYBR® Green kit following the manufacturer's
instructions (Applied Biosystems). Ampliﬁcations were carried out
for 40 cycles, each consisting of 15 s at 95 C and of 30 s at 60 C. A
temperature just below the speciﬁc melting temperature (Tm) was
employed for detection of ﬂuorescence speciﬁc products (MR: Tm
76 C, 18S: Tm 83 C). MR mRNA was quantiﬁed using triplicates of
samples and using the delta-delta CT method (Weil et al., 2006).
The housekeeping gene 18s (Accession No. NR_046237, Forward
primer: CGGCTACCACATCCAAGGAA Reverse Primer: GCTGGAAT-
TACCGCGGCT) was used as an internal reference gene.
2.6. Western blot
Kidney, DRG, spinal cord or peripheral (sciatic) nerve from adult
rats were solubilized according to Weems et al. (1996). Western
blot analysis was performed as previously described (Ji and Rupp,
1997;Mousa et al., 2010). Brieﬂy, the samples were homogenized in
RIPA-Buffer and the lysate was centrifuged at 16.000 g for 20 min.
The protein concentration of the supernatant wasmeasured using a
BCA assay (Pierce, Rockford, IL, USA). Subsequently 10e20 mg pro-
tein were denatured in SDS sample buffer (5 loading buffer:
200 mM Tris, pH 6.8, 10% SDS, 20% glycerol, 10% 2-mercaptoethanol
and 0.05% bromophenol blue; ﬁlled up with RIPA buffer) for
10 min at 80 C. The extracts were separated using 7.5% Mini-
PROTEAN TGX Stain-Free Precast Gels (Bio-Rad, Copenhagen,
Denmark). After SDS-electrophoresis, the gels were activated using
UV light. The activated gel was then electrophoretically transferred
to a nitrocellulose membrane using the Trans-Blot Turbo Transfer
System (Bio-Rad Laboratories GmbH, München, Germany). After
blotting the protein transfer was visualized by taken a UV light
exposure image. The membranes were blocked in 3% BSA for 2 h
and incubated with rabbit anti-MR (Santa Cruz, 1:2.000, in 3% BSA)
overnight at 4 C. This antibody has been proven to be highly
speciﬁc followingMR-transfection and knock-down in different cell
lines (O'Hara et al., 2014; Jeong et al., 2009). After incubation with
the secondary antibody (peroxidase-conjugated goat anti-rabbit,
1:40.000, Jackson ImmunoResearch) for 2 h at room temperature,
reactive protein bands were digitally visualized using ECL solutions
(SuperSignalWest Pico, Thermo Scientiﬁc) in ChemiDocMP Imager.
Finally, the blots were reprobed with monoclonal mouse anti-beta
Actin antibody (1:20.000; Sigma Aldrich) as an internal standard.
Experiments were repeated three times.
2.7. Immunohistochemistry
2.7.1. Tissue preparation
Adult rats were deeply anesthetized with isoﬂurane and trans-
cardially perfused with 100 ml warm saline, followed by 300 ml 4%
(w/v) paraformaldehyde in 0.16 M phosphate buffer solution (pH
7.4). After perfusion the subcutaneous tissue, sciatic nerve, DRG and
spinal cord were removed and ﬁxed in the same ﬁxatives for
90 min, and then cryoprotected overnight at 4 C in PBS containing
10% sucrose. The tissues were then embedded in tissue-Tek com-
pound (OCT, Miles Inc. Elkhart, IN) and frozen. DRG or sciatic nerve
sections (8 mm thick) were mounted onto gelatin coated slides but
spinal cord and subcutaneous sections (50 mm thick) collected in
PBS (ﬂoating sections).
2.7.2. Double immunoﬂuorescence staining
Double immunoﬂuorescence staining was processed as
described previously (Mousa et al., 2007). Tissue sections wereincubated for 60 min in PBS containing 0.3% Triton X-100, 1% BSA,
10% goat serum (Vector Laboratories, CA, USA) (blocking solution)
to prevent nonspeciﬁc binding. The sections were then incubated
overnight with the following primary antibodies: polyclonal rabbit
antibodies against MR (Dr. M. Kawata) (dilution of 1:2000) in
combination with a polyclonal guinea pig anti-CGRP (Peninsula
Laboratories, 1:1000), anti-NF200 (Sigma, 1:1000), goat polyclonal
anti-trkA, anti-trkB or anti-trkC (R&D,1:500). After incubationwith
primary antibodies, the tissue sections were washed with PBS and
then incubated with Alexa Fluor 594 donkey anti-rabbit antibody
(Vector Laboratories) in combination with Alexa Fluor 488 goat
anti-guinea pig, anti-mouse or anti-chicken antibody (Invitrogen,
Germany). Thereafter, sections were washed with PBS, and the
nuclei stained bright blue with 40-6-Diamidino-2-phenylindole
(DAPI) (0.1 mg/ml in PBS) (Sigma). Finally, the tissue sections were
washed in PBS, mounted on vectashield (Vector Laboratories) and
imaged on a confocal laser scanning microscope, LSM510, equipped
with an argon laser (458/488/514 nm), a green helium/neon laser
(543 nm), and a red helium/neon laser (633 nm; Carl Zeiss,
G€ottingen, Germany). Single optical slice images were taken
using 10 or 20 Plan-Neoﬂuar air interface or 40 Plan-Neoﬂuar
oil interface objective lens. The brightness and contrast of the ﬁnal
images were adjusted in Adobe Photoshop 6.0 (Adobe Systems, San
Jose, CA). To demonstrate speciﬁcity of the staining, the following
controls were included as described in our previous studies (Mousa
et al., 2007, 2010): omission of either the primary antisera or the
secondary antibodies. The method of quantiﬁcation for DRG
staining has been described previously (Mousa et al., 2007). For
counting of the total number of neurons, only those immuno-
stained neurons containing a distinct nucleus were counted using
the microscope (40  objective). In a similar way, the number of
GR/MR-, MR/CGRP-, MR/trkA-, MR/trkB-, R/trkC-, NF200-, GFAP- or
OX42-IR neurons was counted and divided by the total number of
MR-IR neurons in each DRG section and represented as percent-
ages. Data were obtained from two sections per rat and four to ﬁve
rats per group.2.8. Von Frey ﬁlament testing
Rats were placed in a plastic cage for half an hour to acclimate
until cage exploration and major grooming activities ceased. At the
bottom of the cage a wire mesh allowed full access to the paws.
Mechanical hind paw withdrawal thresholds were assessed by the
application of a calibrated series of von Frey ﬁlaments of logarith-
mic incremental stiffness (Stoelting, Wood Dale, IL, USA) as
described previously (Dixon, 1980; Chaplan et al., 1994; Mousa
et al., 2016). Von Frey ﬁlament testing were ﬁrstly performed in
all groups before drug application to get baseline values. Then, the
nociceptive responses were reassessed at different time-points
(0e60 min) following drug administrations to determine drug-
related behaviors. Brieﬂy, the resulting pattern of positive and
negative responses were tabulated using the convention,
X ¼ withdrawal; 0 ¼ no withdrawal, and the 50% response
threshold was interpolated using the formula: 50% g thresh-
old¼ (10(xfþkd))/10,000, where xf ¼ value (in log units) of the ﬁnal
von Frey ﬁlament used; k¼ tabular value for the pattern of positive/
negative responses; and d¼mean difference (in log units) between
stimuli. After baseline measurements von Frey thresholds were
reevaluated at different time intervals before and 0e60 min after
i.pl. or i.t. injection of vehicle, the MR agonist aldosterone alone or
in combination with MR antagonist canreonate-K. The mechanical
paw withdrawal thresholds were deﬁned as the mean of 5e6 ani-
mals performed before and after i.pl. or i.t. drug injections.
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The following experiments should identify MR speciﬁc binding
sites in membrane fractions of spinal cord and DRG prepared ac-
cording to our previous binding studies (Mousa et al., 2010;
Shaqura et al., 2004; Z€ollner et al., 2003). Membrane fractions
fromWistar rat spinal cord or DRGwere prepared by homogenizing
them in cold assay buffer (50 mM Tris-HCl, 1 mM EGTA, 5 mM
MgCl2, pH 7.4) and by centrifuging them at 48,000g at 4 C for
20 min. The pellet was resuspended in assay buffer followed by
10 min incubation at 37 C to remove endogenous ligands. The
homogenates were centrifuged again at 48,000 g and resuspended
in assay buffer. Membranes were aliquoted and stored at 80 C
(for details see Z€ollner et al., 2003). Saturation binding experiments
were performed using the speciﬁc MR agonist [3H]aldosterone
(speciﬁc activity 77.4 ci/mmol, Hartmann, Germany). 50e100 mg of
membrane protein was incubated with various concentrations of
1.25e40 nM [3H]aldosterone and 10 mM of unlabeled aldosterone
for 2 h at 30 C in a total volume of 0.5 ml of binding buffer (50 mM
Tris-HCl, 5 mM EDTA, 5 mM MgCl2, 100 mM NaCl, 0.2% bovine
serum albumin). Nonspeciﬁc binding was deﬁned as radioactivity
remaining bound in the presence of 10 mM unlabelled aldosterone.
At the end of the incubation period, bound and free ligands were
separated by rapid ﬁltration over GF/C ﬁlters under vacuum using a
Brandel cell harvester (Gaithersburg, MD, USA). Filters were
washed three times with 4 ml of cold buffer (50 mM Tris-HCl, pH
7.4). Bound radioactivity was determined by liquid scintillation
spectrophotometry after overnight extraction of the ﬁlters in 3 ml
of scintillation ﬂuid. All experiments were performed in duplicate
and carried out at least three times. Nonspeciﬁc binding was sub-
tracted from all [3H]aldosterone data. Bmax and Kd values in satu-
ration binding assays were determined by nonlinear regressionFig. 1. Detection of MR mRNA and protein in rat kidney, spinal cord (SC), dorsal root gan
in kidney, spinal cord, dorsal root ganglia and sciatic nerve of naïve rats. A, B: DNA melting p
as the ampliﬁcation proﬁles of the 18S- and MR-speciﬁc cDNA of naïve rats (B). C: column gra
of naïve rats. D: Western blot analysis with a rabbit polyclonal anti-MR antibody shows M
molecular weight of 107 kDa.analysis of concentration-effect curves using GraphPad Prism
(GraphPad Software Inc., CA, USA).
2.10. Statistical analysis
All tests were performed using Sigma Stat 2.03 software (SPSS
Inc., Germany). MRmRNA data are expressed asmeans± s.e.m. Paw
withdrawal thresholds determined by von Frey ﬁlament testing
were expressed as means ± s.e.m and statistically analyzed by one
way or two-way ANOVA and post-hoc by Dunnett's or Tukey test,
respectively. For all statistical tests, signiﬁcance was assumed at
P < 0.05.
3. Results
3.1. Identiﬁcation of spinal cord and DRG mineralocorticoid
receptor speciﬁc mRNA and protein
Using a highly speciﬁc primer pair (Fig. 1A) an expected MR
speciﬁc 85 bp PCR-productwas identiﬁed in the kidney of naive rats
(Fig. 1B, C). Similar to the expression in the kidney the same MR
speciﬁc PCR-productwas also detected in the spinal cord and dorsal
root ganglia of these naïve rats (Fig. 1C). This was consistent with
the demonstration of a MR speciﬁc protein band at 107 kDa not
only in the kidney, but also in the spinal cord, dorsal root ganglia,
and sciatic nerve (Fig. 1D).
3.2. Localization of spinal MR on central nerve terminals of
nociceptive neurons
In the dorsal horn of the spinal cord there was abundant
colocalization of MR with CGRP, a marker for nociceptive neuronsglia (DRG) and sciatic nerve (SN). Quantiﬁcation of MR mRNA using Taqman® qRT-PCR
roﬁles using a 18S- (as internal standard gene) and MR-speciﬁc primer pair (A) as well
ph represents the per cent of MRmRNA expression relative to the expression in kidneys
R speciﬁc protein bands from kidney, SC, DRG and SN of naïve rats with an expected
M. Shaqura et al. / Neuropharmacology 107 (2016) 251e261 255(Fig. 2). This colocalization occurred mainly from incoming sensory
neurons in Rexed laminae I and II of the grey matter of the spinal
cord, whereas few scattered neuronal cells could also be identiﬁed
in Rexed laminae III and IV (Fig. 2). Interestingly, MR did not
colocalize with GFAP, a marker for astrocytes, and only very rarely
with OX-42, a marker for microglia, within the spinal cord of naïve
rats indicating its main neuronal localization (Fig. 2).3.3. Colocalization of MR primarily with CGRP and trkA in
nociceptive DRG neurons
Double immunoﬂuorescence confocal microscopy showed
abundant colocalization of MR with CGRP (74.9 ± 9.7%) (Fig. 3,
upper panels) and trkA (55.6 ± 7.3%) (Fig. 4, upper panels); how-
ever, there was less colocalization with NF200 (20.8 ± 3.2%) (Fig. 3,
lower panels), trkB (27.7 ± 4.0%) (Fig. 4, middle panels) and trkC
(15.1± 8.6%) (Fig. 4, lower panels) indicating that the MR isFig. 2. Confocal microscopy of double immunoﬂuorescence of MR (red ﬂuorescence) wit
Upper row: almost complete colocalization of MR- (red) with CGRP- (green) immunoreactiv
III and IV (arrow). Middle row: lack of colocalization of MR-immunoreactivity (red) with t
colocalization of MR-immunoreactivity (red) with the microglia marker OX-42 (green) e
Bar ¼ 40 mm. (For interpretation of the references to colour in this ﬁgure legend, the readepredominantly expressed in nociceptive C- and Ad-neurons, but
much less in mechanoreceptive and proprioceptive neurons
(Matsumoto et al., 2012). Approximately 80% of these neurons do
not showcolocalizationwith NF200 (Fig. 3, lower panels) indicating
that the majority are unmyelinated nerve ﬁbres.3.4. Localization of skin MR on peripheral nerve terminals of
nociceptive neurons
Consistently, MR also colocalized to a high degree with the
sensory neuron marker CGRP both in peripheral nerve ﬁbers of the
sciatic nerve (Fig. 5, upper panels) and in branching nerve terminals
within the subepidermal and epidermal layer (Fig. 5, middle
panels), although there were some CGRP-immunoreactive nerve
ﬁbers withoutMR. In addition, MR colocalised to a high degreewith
the sensory neuron marker trkA in branching nerve terminals of
the skin (Fig. 5, lower panels). These nerve terminals extend ash CGRP, GFAP or OX-42 (all green ﬂuorescence) in the dorsal horn of the spinal cord.
ity in Rexed laminae I and II with few, only MR-immunorecative cells in Rexed laminae
he astrocyte marker GFAP (green) throughout the spinal cord. Lower row: almost no
xcept for very few scattered cells with MR- and OX-42 costaining (yellow, arrow).
r is referred to the web version of this article.)
Fig. 3. Confocal microscopy of MR (red ﬂuorescence) and CGRP or NF200 (green ﬂuorescence) double immunoﬂuorescence in DRG of naïve rats. Upper row: coexistence
(double arrow) of MR (red) with CGRP (green) with few cells containing only MR (arrow) or CGRP (arrowhead). Quantitative analysis showed that the number of DRG neurons
coexpressing MR with CGRP was 74.9 ± 9.7%. Lower row: coexistence (double arrow) of MR (red) with NF200 (green) in a small population of cells with the majority containing only
MR or NF200. Quantitative analysis showed that the number of DRG neurons colocalizing MR with NF200 was 20.8 ± 3.2%. Data are shown as means ± SEM. Bar ¼ 40 mm. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Shaqura et al. / Neuropharmacology 107 (2016) 251e261256numerous free nerve endings from the subepidermal into the
epidermal layer (Fig. 5, lower panels). Importantly, theMRwere not
identiﬁed over the entire course of the peripheral nerve ﬁbres in
accompanying Schwann cells.
3.5. Functional role of spinal cord and DRG mineralocorticoid
receptors in nociceptive behavior
To assess the functional relevance of the presence of the MR
exclusively on nociceptive ﬁbres we performed von Frey ﬁlament
testing following the local i.pl. or i.th. administration of increasing
doses of the MR selective agonist aldosterone. The results show a
signiﬁcant dose-dependent decrease in mechanical thresholds of
up to almost 50% following either the i.pl. or i.th. application of
aldosterone (Fig. 6A, B). Co-administration of aldosterone with the
MR selective antagonist canreoante K signiﬁcantly reversed the
decrease in mechanical thresholds following both treatments
(Fig. 6C, D). Whereas nociceptive effects of i.th. aldosterone
administration were observed on both sides, nociceptive effects of
i.pl. aldosterone were seen only ipsi- but not contralateral to the
injection side indicating a local peripheral effect (data not shown).
3.6. Evidence for membrane bound MR
Following the separation of membrane fractions of DRG neurons
and spinal cord by ultracentrifugation MR speciﬁc binding sites
were identiﬁed by use of the MR speciﬁc ligand [3H]aldosterone.
Increasing concentrations of [3H]aldosterone in the presence of
10 mM unlabeled aldosterone led to a speciﬁc saturation curve in
membranes of DRG (Fig. 7A) and spinal cord neurons (Fig. 7B) with
Bmax values of 35.9 ± 5.5 fmol/mg protein and 51.8 ± 6.2 fmol/mg
protein and Kd values of 24.3 ± 7.3 nM and 11.6 ± 3.4 nM, respec-
tively. In line with these ﬁndings and with the antibody speciﬁca-
tions (Table 1), MR-immunoreactivity in DRG neurons of naïve ratswas not identiﬁed in the nuclear but in the cytosol/plasma mem-
brane compartment (Fig. 7C).
4. Discussion
This study systematically examined the exact anatomical local-
ization of MRwithin the spinal cord and peripheral nervous system
of naïve rats. In contrast to previous reports that used different
models of persistent pain (Dong et al., 2012; Sun et al., 2012), our
results demonstrate that MR are expressed mainly in nociceptive
neurons and very rarely in glia cells. In the spinal cord, MR coloc-
alize predominantly with incoming presynaptic CGRP-IR nerve
terminals in Rexed laminae I and II. Only few scattered neuronal cell
bodies in Rexed laminae III and IV were also positive. In addition, in
peripheral nerve ﬁbers of the sciatic nerve and peripheral nerve
endings of the skin MR were restricted predominantly to noci-
ceptive neurons such as unmyelinated C-ﬁbers and Ad-ﬁbers and
colocalized only marginally with myelinated mechanoreceptive or
proprioceptive neurons (Matsumoto et al., 2012). In Schwann cells,
satellite cells, and astrocytes MR could not be identiﬁed under
normal conditions, though a scant few were found in microglia of
the spinal cord. The activation of either spinal or peripheral MR on
these nociceptive neurons by local agonist application resulted in a
dose-dependent reduction in mechanical thresholds of naïve rats.
The use of an MR antagonist demonstrated receptor speciﬁcity.
These rapid effects in nociceptive behavior together with the
presence of neuronal MR speciﬁc membrane binding sites in DRG
and spinal cord suggest a potential rapid non-genomic mechanism
of nociceptive modulation throughMR on the plasmamembrane of
nociceptive neurons.
In recent publications that used different models of persistent
pain, MR have been reported to exist in all peripheral neurons
(Dong et al., 2012) as well as in glia cells (Sun et al., 2012). However,
peripheral neurons were not further distinguished into
Fig. 4. Confocal microscopy of MR (red ﬂuorescence) and trkA, trkB or trkC (all green ﬂuorescence) double immunoﬂuorescence in DRG of naïve rats. Note that the population
of DRG neurons coexpressing MR with trkA (55.6 ± 7.3%) was much higher than that coexpressing trkB (27.7 ± 4.0%) or trkC (15.1± 8.6%). All data are shown as means ± SEM.
Bar ¼ 20 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Shaqura et al. / Neuropharmacology 107 (2016) 251e261 257subpopulations of peripheral neurons and there is no direct proof of
MR in glia cells. Evidence for MR on neurons has been known for a
long time: earlier binding studies already suggested two different
corticoid receptors within the central nervous system (McEwen
et al., 1986) and found evidence for type I (i.e. mineralocorticoid
receptor) and type II corticosteroid receptor gene expression (Reul
et al., 1989). Soon thereafter, type I corticoid receptor (MR)-like
immunoreactivity was ﬁrst reported in the spinal cord (Ahima
et al., 1991). However, no data are available on the exact anatom-
ical localization of MR with regards to speciﬁc subpopulations of
nerve ﬁbers that innervate the periphery. In using a new highly
speciﬁc polyclonal rabbit antibody against the rat MR that does not
cross-react with the glucocorticoid receptor (Ito et al., 2000) we
were able to demonstrate MR immunoreactivity in neuronal cell
bodies of dorsal root ganglia as well as their peripheral (within
skin) and central (within spinal cord) nerve terminals. More
importantly, MR immunoreactive neurons strongly colocalized
with CGRP, a marker for nociceptive C- and Ad-nerve ﬁbers.
Consistently, the majority of MR immunoreactive neurons also
colocalized with trkA (Matsumoto et al., 2012). In longitudinal
sections of the innervating sciatic nerve and in sections of arbor-
izing nerve endings at the dermal-epidermal junction of the skin
the majority of MR immunoreactive axons colocalized with CGRP
which clearly indicates a pivotal role these receptors play in the
modulation of nociception.Indeed in our own behavioral experiments with naïve animals,
we could demonstrate for the ﬁrst time an immediate and almost
50% decrease in mechanical thresholds, i.e. increased sensitivity to
mechanical stimuli, ipsi- but not contralateral to the i.pl. adminis-
tration of aldosterone. This peripheral effect occurred within
10 min, persisted for 40 min and was receptor speciﬁc as a simul-
taneous local injection of a MR selective antagonist reversed this
effect. The same effect was observed at central nerve terminals of
the peripheral sensory neurons when aldosterone with or without
its respective antagonist was given intrathecally. Consistent with
such a pronociceptive effect, previous studies have shown that the
MR selective agonist aldosterone dose-dependently increased the
number of action potentials evoked by suprathreshold current in-
jection in acutely dissociated DRG neurons of naïve rats (Ye et al.,
2014; Dong et al., 2012). Interestingly, other studies have
described antinociceptive effects of aMR antagonist under different
pathological conditions such as low back pain (Ye et al., 2014; Dong
et al., 2012; Sun et al., 2012; Gu et al., 2011) and diabetic neuropathy
(Dong and He, 2013). Thus in line with these ﬁndings of anti-
nociceptive effects by a MR antagonist, we demonstrate that the
application of a MR selective agonist induces nociception under
non-pathological conditions.
In addition to neuronal MR, it is discussed whether MR on glia
cells modulate nociception (Dong et al., 2012). However, whereas
MR immunoreactive glia cells in the hippocampus (Hwang et al.,
Fig. 5. Confocal microscopy of MR (red ﬂuorescence) with CGRP or trkA (green ﬂuorescence) double immunoﬂuorescence in sciatic nerve and subcutaneous tissue. Note that
the majority of MR immunoreactive nerve ﬁbers coexpress CGRP or trkA in sciatic nerve (upper row) or subcutaneous tissue (middle and lower row). Bar ¼ 20 mm. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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et al., 2001) have been convincingly demonstrated, there is no
direct immunohistochemical evidence of MR in glia cells of the
spinal cord or peripheral nerve. Several studies reported the pres-
ence of MR in cell cultures of microglia (Girard et al., 2010; Sierra
et al., 2008; Tanaka et al., 1997), but the evidence was mainly
gained indirectly through MR-mediated effects. Here in naïve rats
we could identify a remote colocalization of MRwith the microglial
marker OX-42 (Fig. 2) and found no presence of MR in astrocytes,
satellite cells or Schwann cells (Fig. 2). This might be different
under pathological conditions such as nerve injury when expres-
sion of MR in glia cells might be up-regulated (Dong et al., 2012),
yet direct evidence is still missing.
The observation in our study that acute nociceptive effects occur
within a few minutes after local MR agonist application strongly
questions a genomic provenance, particularly since MR at the pe-
ripheral nerve terminal need to travel retrogradely the entire
length of the sciatic nerve in order to reach the cell nucleus and
alter gene expression. Instead, recent evidence repeatedly shows
that neuronal MR agonists may also elicit their effects through non-
genomic ways (Chatterjee and Sikdar, 2014; Groeneweg et al.,2012). These non-genomic pathways can be elicited either by
directly interfering with intracellular signaling pathways or by
interfering with membrane bound structures such as ion channels
and G-protein coupled receptors (Chatterjee and Sikdar, 2014;
Groeneweg et al., 2012). Indeed, we further substantiated the evi-
dence for a putative non-genomic pathway in our binding experi-
ments. These demonstrated saturation binding with increasing
concentrations of the radiolabeled ligand [3H]aldosterone in the
pure membrane fraction of DRG neurons indicating MR speciﬁc
binding sites. Consistently, our immunoﬂuorescence confocal mi-
croscopy showed that MR were not identiﬁed in the nuclear but in
the cytosol/plasma membrane compartment of DRG neurons.
Moreover, we identiﬁed MR binding sites in the spinal dorsal horn
which might reﬂect both MR receptors on central endings of pri-
mary afferent nociceptors and MR receptors on central neurons. In
agreement with our ﬁndings, convincing evidence for membrane
bound MR is also provided by electron microscopy studies in pre-
synaptic terminals and postsynaptic densities of synaptic areas of
the brain (Prager et al., 2010; Johnson et al., 2005). In contrast to
genomic MR, membrane bound MR elicit their effects within
seconds-to-minutes and have been shown to increase synaptic and
Fig. 6. Von Frey ﬁlament testing of mechanical sensitivity following the local i.pl. or i.t. application of aldosterone (A, C) with and without the MR antagonist canreonate-K
(B, D). A,B: Local intraplantar (A) or i.t. (C) injection of increasing doses of the MR agonist aldosterone resulted in the immediate fall of mechanical withdrawal thresholds in
hindpaws of naïve rats (P < 0.5, one-way ANOVA, post-hoc Dunnett's test, n ¼ 6). Peak effects occurred at 10 min and by 60 min the mechanical withdrawal thresholds returned to
preinjection baseline values. B, D: Intraplantar or i.t. injection of aldosterone in combination with the MR antagonist canreonate-K fully reversed MR agonist-induced mechanical
hypersensitivity (P < 0.5, two-way ANOVA, post-hoc Tukey test, n ¼ 6). Data are expressed as means ± SEM.
Fig. 7. Saturation binding analysis of MR speciﬁc binding sites in cell membranes of DRG neurons (A) and the dorsal horn of the spinal cord (B) with the MR selective
radiolabeled ligand [3H]aldosterone. In naive rats, increasing concentrations of [3H] aldosterone (0.25e40 nM) in the presence of excess of cold aldosterone (10 mM, to subtract
nonspeciﬁc binding) resulted in saturation binding in DRG (A) and spinal cord (B) neurons with Bmax values of 35.9 ± 5.5 fmol/mg protein and 51.8 ± 6.2 fmol/mg protein and Kd
values of 24.3 ± 7.3 nM and 11.6 ± 3.4 nM nM, respectively. Data are expressed as means ± SEM. C) Confocal immunoﬂuorescence images show that MR green ﬂuorescence labeling
was not identiﬁed in the nuclear but in the cytosol/plasma membrane compartment. DAPI blue ﬂuorescence labeling represents nuclear staining (Bar ¼ 40 mm). (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Dong et al. have shown in dorsal root ganglion neurons of naïve rats
that the MR agonist aldosterone dose-dependently increased the
number of action potentials evoked by suprathreshold current in-
jection (Dong et al., 2012).
5. Conclusions
Taken together, MR predominantly colocalized with peripheral
nociceptive neurons and only marginally with myelinated mecha-
noreceptive and proprioreceptive neurons underscoring their
pivotal role in themodulation of nociception. MRwere not detected
in most of the glia cells e only scarcely in spinal microglia e indi-
cating no relevant functional role of glia-derived MR at least in
naïve rats. However, this might change under pathological condi-
tions that are known to elicit glia activation, e.g. neuropathic pain
(Ji et al., 2013). For the ﬁrst time we can show immediate effects
upon activation of MR on peripheral nociceptive neurons that are
most likely due to non-genomic mechanisms. This is further sub-
stantiated by the identiﬁcation of membrane bound MR speciﬁc
binding sites in neurons of dorsal root ganglia and spinal cord.
Therefore, the crucial role of MR on nociceptive neurons and their
impact on nociceptive behavior most likely due to immediate non-
genomic effects has to be considered under normal but more so
under pathological conditions in future studies.
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